{"name":"Samsung Bioepis Co., Ltd.","slug":"samsung-bioepis-co-ltd","ticker":"","exchange":"","domain":"samsungbioepis.com","description":"","hq":"Incheon","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"SB27","genericName":"SB27","slug":"sb27","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"SB5","genericName":"SB5","slug":"sb5","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"SB5 (Adalimumab Biosimilar)","genericName":"SB5 (Adalimumab Biosimilar)","slug":"sb5-adalimumab-biosimilar","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Adalimumab PFS and Pen","genericName":"Adalimumab PFS and Pen","slug":"adalimumab-pfs-and-pen","indication":"Rheumatoid Arthritis","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Herceptin (trastuzuamb)","genericName":"Herceptin (trastuzuamb)","slug":"herceptin-trastuzuamb","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"Prolia® (Denosumab)","genericName":"Prolia® (Denosumab)","slug":"prolia-denosumab","indication":"Treatment of osteoporosis in postmenopausal women","status":"phase_3"},{"name":"SB8","genericName":"SB8","slug":"sb8","indication":"Metastatic colorectal cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"EU Remicade","genericName":"EU Remicade","slug":"eu-remicade","indication":"Other","status":"phase_1"},{"name":"Soliris (eculizumab)","genericName":"Soliris (eculizumab)","slug":"soliris-eculizumab","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Lucentis (ranibizumab)","genericName":"Lucentis (ranibizumab)","slug":"lucentis-ranibizumab","indication":"Neovascular (wet) age-related macular degeneration","status":"marketed"}]}],"pipeline":[{"name":"SB27","genericName":"SB27","slug":"sb27","phase":"phase_3","mechanism":"SB27 is a biosimilar to adalimumab, a TNF-alpha inhibitor.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"EU Remicade","genericName":"EU Remicade","slug":"eu-remicade","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"SB5","genericName":"SB5","slug":"sb5","phase":"marketed","mechanism":"SB5 is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease"],"catalyst":""},{"name":"SB5 (Adalimumab Biosimilar)","genericName":"SB5 (Adalimumab Biosimilar)","slug":"sb5-adalimumab-biosimilar","phase":"marketed","mechanism":"SB5 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Soliris (eculizumab)","genericName":"Soliris (eculizumab)","slug":"soliris-eculizumab","phase":"phase_3","mechanism":"Soliris works by inhibiting the complement system by blocking the action of C5.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)","Atypical hemolytic uremic syndrome (aHUS)"],"catalyst":""},{"name":"Adalimumab PFS and Pen","genericName":"Adalimumab PFS and Pen","slug":"adalimumab-pfs-and-pen","phase":"phase_2","mechanism":"TNF-alpha inhibitor","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Ankylosing Spondylitis","Crohn's Disease","Ulcerative Colitis"],"catalyst":""},{"name":"Herceptin (trastuzuamb)","genericName":"Herceptin (trastuzuamb)","slug":"herceptin-trastuzuamb","phase":"phase_3","mechanism":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)","HER2-positive metastatic gastric cancer"],"catalyst":""},{"name":"Lucentis (ranibizumab)","genericName":"Lucentis (ranibizumab)","slug":"lucentis-ranibizumab","phase":"marketed","mechanism":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.","indications":["Neovascular (wet) age-related macular degeneration","Macular edema following retinal vein occlusion","Diabetic macular edema","Diabetic retinopathy","Myopic choroidal neovascularization"],"catalyst":""},{"name":"Prolia® (Denosumab)","genericName":"Prolia® (Denosumab)","slug":"prolia-denosumab","phase":"phase_3","mechanism":"Prolia works by binding to RANKL, a protein involved in the formation and activation of osteoclasts, which are cells that break down bone.","indications":["Treatment of osteoporosis in postmenopausal women","Treatment of bone loss in patients with hormone ablation for prostate cancer","Treatment of bone loss in patients with hormone receptor-positive breast cancer","Treatment of giant cell tumor of bone","Treatment of osteogenesis imperfecta"],"catalyst":""},{"name":"SB8","genericName":"SB8","slug":"sb8","phase":"phase_3","mechanism":"SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-squamous non-small cell lung cancer","Metastatic breast cancer","Renal cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPa2RrZDJKcllvM3BuMS1MS1N1T2pNTDdZRXkwYjZPZk1MSVc2SGhLaUpwbXJGTWFZSTVqUnJ1UFExRUVtdm1iNERzeTF5RHgwdzB4elZ4dFA1dDk3SGtpWFlZcTBCTTZzcXZyWThnMnRHSGswNnY3VlRad2pJNEZXa1RnNnNXWGZuREM4M3dJMTNEUHRsU0U5N0p1WlhIWVYzbFFB?oc=5","date":"2026-03-16","type":"deal","source":"BioWorld News","summary":"G2Gbio secures license deal, ₩20B investment from Samsung Epis - BioWorld News","headline":"G2Gbio secures license deal, ₩20B investment from Samsung Epis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNOFRkdlVyeXVEVzRMMDV3UThRWkRwdEd2WWxBRS01THZnQ0piaUxsX1oxdGNGT1Y5eEZnczZLajYzeF9Fd183Z2dYS2RzRnZESFk5VUZHN0l5Tl9qbUxnT25wc1VneDFVR0RuR0s4a1lGenBQODZ0Uy1RSGxmY0tOaE9EMU5obWRqd1RJWm9TWEw4YU0xc2tsenFzSVNuaHhOUEVKSi14LVphbF9VRlZLT2tCYkJOZ9IBckFVX3lxTE9yS1hGSDhoXzhOdS04dHU0bENkWkVoT1RNV3p3Sk4yTE5xdm1hQ2RSQVNIdVRFeG1OR1BjaTNtZWdTQlFhbXJtV2dVTEhrenUwcFVyVnNnTDdVaFdwbm9seWpoZlI3bTNGWUVBV3g0cldwdw?oc=5","date":"2026-02-12","type":"patent","source":"Law360","summary":"Regeneron, Samsung Bioepis Settle Eye Med Patent Claims - Law360","headline":"Regeneron, Samsung Bioepis Settle Eye Med Patent Claims - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQR0RmTVR2RW4zMXI2YW50cHgtUHhKcVU1c25CakZUX1BmdWlpNmk3UFJlRG9VeFlBZy16eDZ1WElEV3NjYzFnY0t2cWwyY0NwVXJYZEdOS3JuQnhycmpvWDY5NWlYSkxJb0lhQThDMnoxMVJvemNUa1RncWtEMldXZVd5dXNPcktwcllPc0RuVUNKcGJKSEdPYUU1TWlwQVUxaEJzR2xWYzVNbDRWalk5TFNBM0Q1TlRKV1pCUUNXYlM?oc=5","date":"2026-02-05","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Samsung Biologics Co Ltd: The Silent Giant Wall Street Won’t Shut Up About - AD HOC NEWS","headline":"The Truth About Samsung Biologics Co Ltd: The Silent Giant Wall Street Won’t Shut Up About","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQQzRRaWxaX0Y4TVVjdVdRREgyYjFaVDZRMjJBak1mSGxUdC1WOWV5b0VGUW90RGcyQ05fcXh4RkNyRzdvSmJQMy1fc1M5UmNPWEFGZDlkalJXRmEyYTlvTlpuMWd6RTF0d1JPZzJHY0lZWkE5MjZ5MVpTbzRVOHJnczBR?oc=5","date":"2026-01-22","type":"regulatory","source":"jdsupra.com","summary":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 22, 2026 - jdsupra.com","headline":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 22, 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9jNVR4c3pDbnFGSWwtcV9YUVVUQWV6aVVwd0hfU1VTb3dxY29PX1pQYkJVWGZ4cVR1VDIzbXFOdmJhY1NXbUwyWld3VVdOMHp3bXVwNlJ5LWRXdWxhTFZKUklVdmJYbmlGTm8tN2ln?oc=5","date":"2026-01-14","type":"pipeline","source":"KED Global","summary":"Samsung Biologics weighs acquisition of weight-loss drug plant in US - KED Global","headline":"Samsung Biologics weighs acquisition of weight-loss drug plant in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNel92N3Jrd1h6aV9MMkl2d1dUcDNmUFE2LUpkV2RhVm9fNmpLSmlIMzV1UzRSZXM1QkhiMUgxNEJlR1R2T0txZ1RkbU1fTzhmWVVfNjBpRWkxamZJWmp3c0VKd1BXWElwbjc1OVpfNmZTemF6ZjJqTy0wTURHaG9PX0dqS1ZuZEVnY1NRTFFqSTBSV3BSX0JnQVFPTWRYeXM?oc=5","date":"2025-12-23","type":"regulatory","source":"Contract Pharma","summary":"Samsung Bioepis’ Stelara Biosimilar Approved in Japan - Contract Pharma","headline":"Samsung Bioepis’ Stelara Biosimilar Approved in Japan","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9qNy1UNS1rXzh3dUw2aFFTQWRoSC1FRnZoXzRqNDRrNU0xdEdCVzJ5VGpITVpOY2VVOWdYYm5BaHVJWU9jcXFRUk9NZzVxb2Fza0ptdWRWd09jS3dwYU1Mb0c0dllHNDMwUnFWdmxn?oc=5","date":"2025-12-22","type":"deal","source":"KED Global","summary":"Samsung Biologics to buy its first US drug factory from GSK for $280 mn - KED Global","headline":"Samsung Biologics to buy its first US drug factory from GSK for $280 mn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQVm5mdUY1c09oZDRveTJMcmdXS1JyakM1dWYzMjFZLThZbVlFS3Z5NkxXTjFCRGdhdWJIR1Z5OWNmaXV1V1Nhck1EcE9fZ193RUhKTzg5VlM1WjdXRDVfNS1OUTlhUldXVDJ6dVBINHV2SHRLZkIwWVBOSVVNRDdEUGtJY0x6R2gtRFdfSmhHbjFDeHhteXdYSDk0dzE3RW1tRDc0UkxJcU5MOG5CNGlPLXpjX2ZkelV4YWt0bjNPbHV6TXNJcFZjWlFBOWdxZw?oc=5","date":"2025-12-21","type":"deal","source":"Reuters","summary":"Samsung Biologics to buy US drug production facility from GSK for $280 million - Reuters","headline":"Samsung Biologics to buy US drug production facility from GSK for $280 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNc09IX19GT0NCQlduVW1GSzhnWkNDUGZzQWtrR1N0OFV3ZG11NzhvQnZ3NFNnbnRZbzJxSTJOYTlJMVVTb0dWdnZIOGVJWW8wem1EZ0dlQ1RzSUdCd3YtYTdENDdlVnhxXzIyTW02RGpoQngyTTNQUjRoSDFmZUFUcUZEY1hmUldubXN3QWExQzkzNWd3Vk1seEhuSWJvd3k1MEJ4WUVLaHFaQ0N5ZU1hOUo2WFAzMHZLd3FqcTM0Z3daVmNYbEgxWnNJbWhhRklZOFd3VmtsNnVnOEVteTRPUENwcVl1NHpNVU8xS2l4bWJTS1RNaTMxSGhCUXZEa2Q1V0dRd2h5eFJLUTJETTBVMFB3cw?oc=5","date":"2025-07-17","type":"patent","source":"businesswire.com","summary":"Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - businesswire.com","headline":"Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the Unite","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZl83WFh5ekp0NGcybVBWWWc1ak1reHpJZXdDWmZPakhmTVhBc1NPYnU5N01NUC1NdDJDVkR5bU5fOFpObWhIQmF6RlYtckM2Um1DNWdQR1FzNnIycXNYekpHZlBGSFBxc3dBTGNTaWNvcmp3R0lsd3VSR01XaXpMWmZsNzNkckRfaTlDVGZKVThnTkVyTzQ1bXBIVThGQzRWZF9mZUxkbmZpUQ?oc=5","date":"2025-07-17","type":"patent","source":"Contract Pharma","summary":"Samsung Bioepis Taps Harrow for U.S. Eye Biosimilar Portfolio - Contract Pharma","headline":"Samsung Bioepis Taps Harrow for U.S. Eye Biosimilar Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNOWpWRHQ5UWlqemdvZ1dCZF9JZEM2U3NGbTR2aDJ6cXNkQlNxUEEtV0ZRaWVZQm1hUGduNHhtcEF6RG5YT3hiYlBSYlhreTV0YXRSc0xnYjhqRDA3N3FWdS05NlhyaTM1NHBXQ1p2R1FHZG9mTmJFbzhZOU9ERHdpWVhhSzVXdHY1TDhqUFNwT2RpM2pYVWt1c2xmQWlSYTZISm5TRGJNd2huN2M2QTYxdmhHQmswX1U?oc=5","date":"2025-06-09","type":"deal","source":"BioPharma APAC","summary":"Samsung Bioepis Partners with NIPRO to Expand Biosimilar Access in Japan - BioPharma APAC","headline":"Samsung Bioepis Partners with NIPRO to Expand Biosimilar Access in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNdlZ0dzZjM1JudGFPeWxXSTVfejdXbWJFZjJqRGpKc1BiQmtkUlNwTlhmOVZxR19XS2t6UlU4ZFMySWg2dWxKVVZlclVhdXUxem9XMnpmcmdWTXQ1b2N4RHRjY2FpOXRwSWFEMDA3YWZfWHVIaDMzRldFdmRwLVlnZUVBd29vdzV0Y2pTQTZ4LWZJMk9VemhHRDVsem9YU2pCQTZULVVUT1VrTFVkVEp2WXNNdXYzSkxYMHJhLUZ1RQ?oc=5","date":"2025-05-22","type":"pipeline","source":"Fierce Pharma","summary":"CDMO Samsung Biologics telegraphs spinoff of biosim unit - Fierce Pharma","headline":"CDMO Samsung Biologics telegraphs spinoff of biosim unit","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_3":5,"phase_1":1,"marketed":3,"phase_2":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}